Fortner, Renée TSchock, HelenaLe Cornet, CharlotteHüsing, AnikaVitonis, Allison FJohnson, Theron SFichorova, Raina NFashemi, TitilayoYamamoto, Hidemi STjønneland, AnneHansen, LouiseOvervad, KimBoutron-Ruault, Marie-ChristineKvaskoff, MarinaSeveri, GianlucaBoeing, HeinerTrichopoulou, AntoniaPapatesta, Eleni-MariaLa Vecchia, CarloPalli, DomenicoSieri, SabinaTumino, RosarioSacerdote, CarlottaMattiello, AmaliaOnland-Moret, N CharlottePeeters, Petra HBueno-de-Mesquita, H B AsWeiderpass, ElisabeteQuirós, J RamónDuell, Eric JSanchez-Perez, Maria-JoseNavarro, CarmenArdanaz, EvaLarrañaga, NereaNodin, BjörnJirström, KarinIdahl, AnnikaLundin, EvaKhaw, Kay-TeeTravis, Ruth CGunter, MarcJohansson, MattiasDossus, LaureMerritt, Melissa ARiboli, ElioTerry, Kathryn LCramer, Daniel WKaaks, Rudolf2023-01-252023-01-252017-12-11http://hdl.handle.net/10668/11826CA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non-cases. Anti-CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non-cases. We investigated these objectives using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to four matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2-year lag-time intervals were calculated using conditional logistic regression calibrated toward the absolute risk estimates from a pre-existing epidemiological risk model as an offset-variable. Anti-CA125 levels alone did not discriminate cases from controls. For cases diagnosedenCA125MUC16anti-CA125 antibodiesautoantibodiesearly detection markersovarian cancerAdultAgedArea Under CurveAutoantibodiesBiomarkers, TumorCA-125 AntigenCase-Control StudiesCohort StudiesEarly Detection of CancerFemaleHumansMembrane ProteinsMiddle AgedOvarian NeoplasmsROC CurveSensitivity and Specificityresearch article29159934open access10.1002/ijc.311641097-0215PMC5805613https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.31164https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805613/pdf